Page 2 of 6
events (adverse events) and the number of patients who made proteins that bind to
mepolizumab (anti-mepolizumab antibodies).
Which medicine was studied?
Patients knew that they were receiving mepolizumab (see figure below). This is called
an open-label study.
Study design
Which patients were included in this study?
Studies have a list of requirements for patients who can enrol (inclusion criteria) and
those who can’t (exclusion criteria). For this study, the main inclusion and exclusion
criteria are listed below.
Males and females with HES who completed Study 200622 were included in this
study.
Males and females were excluded from the study if they had:
• An adverse event that the study doctor thought was caused by the study
medicine (side effect) and the study medicine was withdrawn during
Study 200622.
• Cancer or liver disease during or after participating in Study 200622.
• Any other disease(s) that the study doctor thought would affect the results
of the study.